Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: gg cox who wrote (12)	10/28/2002 6:38:17 PM
From: gg cox	Read Replies (1) \| Respond to of 66

biz.yahoo.com Skin test for coronary artery disease showcased to cardiologists at Canadian Cardiology Congress Monday October 28, 1:14 pm ET EDMONTON, AB, Oct. 28 /CNW/ - A non-invasive skin test for coronary artery disease, developed by predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News), will be showcased at the Canadian Cardiovascular Congress beginning today in Edmonton, Alberta. The three- minute, painless test is a professional point-of-care skin test cleared for sale in Canada, the U.S., and Europe. IMI's Canadian marketing partner, McNeil Consumer Healthcare, will be featuring and demonstrating the predictive test in its booth at the Congress, the largest cardiovascular meeting in Canada. "There is a significant role for an effective, non-invasive test that assesses a person's risk for coronary artery disease," said Dr. Brent Norton, IMI President and CEO. "Raising awareness of this new approach in the medical community is a priority, and events like the Canadian Cardiovascular Congress are important opportunities to build a foundation of acceptance." About IMI IMI is a world leader in predictive medicine. IMI is dedicated to developing rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer. IMI's lead product is a non-invasive skin test for coronary artery disease. IMI's cancer products in development include ColorectAlert(TM), a screening test for colorectal cancer, and LungAlert(TM), a screening test for lung cancer. For further information, please visit the company's web site at www.imimedical.com. This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings. For further information Andrew Weir, Director, Communications, (416) 222-3449 x27, aweir@imimedical.com Richard Land, Karin Oloffson, Jaffoni & Collins Incorporated, (212) 835-8500 or imi@jcir.com